Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Immunological Investigations|August 5, 2022
<i>IKBKE</i> and <i>BANK1</i> Polymorphisms and Clinical Characteristics in Chinese Women with Systemic Lupus ErythematosusPing Zhang, Jianzhao Zhai, Kefen Wang, et al.
Clinical Rheumatology|February 21, 2022
Analysis of WDFY4 rs7097397 and PHLDB1 rs7389 polymorphisms in Chinese patients with systemic lupus erythematosusJianzhao Zhai, Ping Zhang, Naidan Zhang, et al.
BMC Immunology|January 23, 2026
PHLDB1 and WDFY4 as dual-state biomarkers in SLE pathogenesis and lupus nephritis predictionJianzhao Zhai, Lei Zhang, Wei Jia, et al.
Journal of Cancer Research and Clinical Oncology|May 16, 2022
Allele frequency and proportion defined by circulating tumor DNA profiling predict tyrosine kinase inhibitors' therapeutic outcomes for non-small cell lung cancerJiajia Song, Ling Bai, Jianzhao Zhai, et al.
Clinical and Experimental Rheumatology|June 24, 2024
WNT16 as a promising biomarker for systemic lupus erythematosus and its role in regulating cell proliferation and apoptosisKefen Wang, Yiheng Jiang, Jianzhao Zhai, et al.
Scandinavian Journal of Immunology|November 13, 2019
The value of anti-rods and rings antibodies in Western China population: A retrospective studyLei Zhang, Jianzhao Zhai, Lu Wang, et al.
Clinical Immunology (Orlando, Fla.)|April 27, 2025
Peripheral T-cell subset activation in NMDAR encephalitis: Insights into pathogenesis and biomarker potential for disease monitoringMinjin Wang, Jierui Wang, Jianzhao Zhai, et al.
Laboratory Medicine|August 20, 2021
Anti-Golgi Antibody as a Potential Indicator for Rheumatoid ArthritisJianzhao Zhai, Jing Liao, Minjin Wang, et al.
Thoracic Cancer|April 1, 2026
Transcriptomic Determinants of Circulating Immunity Predict Immune-Related Adverse Events (irAEs) in Cancer Patients Receiving PD-1/PD-L1 BlockadeLiting You, Jianzhao Zhai, Zhaodan Xin, et al.
International Immunopharmacology|June 13, 2023
Immunogenetic polymorphisms predict therapeutic efficacy and survival outcomes in tumor patients receiving PD-1/PD-L1 blockadeZhaodan Xin, Liting You, Jin Li, et al.
Pageof 1